Table 3.
Significance of baseline and baseline-treatment interaction in the analysis of change in HAM-D at week 10 from paroxetine and venlafaxine studies
| Paroxetine | Overall Model (Pbo + Parox) | Placebo only | Paroxetine only | |
|---|---|---|---|---|
| Biomarker | Baseline | Baseline*Treat. | Baseline | Baseline |
| TNFα | p = 0.155 | p = 0.085 | p = 0.842 | p = 0.036 |
| IL-6 | p = 0.567 | p = 0.125 | p = 0.600 | p = 0.104 |
| IL-10 | p = 0.152 | p = 0.054 | p = 0.869 | p = 0.009 |
| PAI1active | p = 0.577 | p = 0.834 | p = 0.798 | p = 0.504 |
| BDNF | p = 0.138 | p = 0.956 | p = 0.467 | p = 0.270 |
| MMP9 | p = 0.615 | p = 0.790 | p = 0.561 | p = 0.557 |
| TNFRII | p = 0.958 | p = 0.324 | p = 0.496 | p = 0.305 |
| CRP | p = 0.467 | p = 0.278 | p = 0.853 | p = 0.225 |
| Venlafaxine | Overall Model (Pbo + Venla) | Placebo only | Venlafaxine only | |
| Biomarker | Baseline | Baseline*Treat. | Baseline | Baseline |
| TNFα | p = 0.893 | p = 0.973 | p = 0.948 | p = 0.745 |
| IL-6 | p = 0.944 | p = 0.574 | p = 0.698 | p = 0.943 |
| IL-10 | p = 0.842 | p = 0.741 | p = 0.958 | p = 0.877 |
| PAI1active | p = 0.309 | p = 0.927 | p = 0.466 | p = 0.581 |
| BDNF | p = 0.603 | p = 0.511 | p = 0.814 | p = 0.310 |
| MMP9 | p = 0.333 | p = 0.860 | p = 0.646 | p = 0.424 |
| TNFRII | p = 0.742 | p = 0.099 | p = 0.157 | p = 0.216 |
| CRP | p = 0.001 | p = 0.259 | p = 0.005 | p = 0.078 |
Analyses of covariance accounting for the effects of HAM-D baseline value, gender and centre, as well as biomarker baseline and treatment by biomarker baseline interaction
Bold: p < 0.05; italics: 0.05 < p < 0.1